← boardnext 2027-09-30
IVA
Inventiva Pharmadistress 1/10 · well-funded / low risk$4.41-3%today-38% from 52w high
Lead: NASH - Nonalcoholic Steatohepatitis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$231M
Runway
2.2 yrs
Shares 1y
0%
Price & events
-37.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-2.4%
1W
+18.9%
1M
-15.4%
3M
-38.3%
6M
+32.8%
1Y
+74.2%
2Y
-68.2%
5Y
-69.4%
All
Overview
- Market Cap
- $852.18M
- Enterprise Value
- $779.68M
- Volume
- 92.44K
- 52 Week Range
- $3.04 – $7.15
- Total Shares
- 193.24M
- Float Shares
- 160.69M
- Short %
- 0.64%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 26.12%
- RVOL
- 0.07x
- Beta
- 0.89
Pipeline stages · 1 programs
IVA337
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09-30 Estimated 50% readout ~2027-12-14 | Phase 3 | IVA337 | NASH - Nonalcoholic Steatohepatitis | — | active not recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 193,236,978 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+243% upside) · 13 analysts
- 2026-07-17Cantor FitzgeraldOverweight
- 2026-03-19Truist SecuritiesBuy
- 2026-01-28BarclaysOverweight
- 2026-01-12Leerink PartnersOutperform
- 2025-11-18GuggenheimBuy
- 2025-11-06Wolfe ResearchOutperform
Competitors — NASH - Nonalcoholic Steatohepatitis
Recent news
- 2026-07-17Cantor Fitzgerald Initiates Inventiva SA ADR at Overweight - Moomoo
- 2026-07-17Cantor Fitzgerald initiates Inventiva stock with overweight rating By Investing.com - Investing.com South Africa
- 2026-07-17Cantor Fitzgerald initiates Inventiva stock with overweight rating - Investing.com
- 2026-07-15Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring - Yahoo Finance
- 2026-07-12Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound - Yahoo Finance
- 2026-07-09[6-K] Inventiva S.A. Current Report (Foreign Issuer) | IVA SEC Filing - Form 6-K - Stock Titan
- 2026-07-06Inventiva (NASDAQ: IVA) shareholders approve most 2026 meeting resolutions - Stock Titan
- 2026-07-03IVA News | INVENTIVA SA - ADR (NASDAQ:IVA) - ChartMill
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.